Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations.

Authors

Changwei Wang, Prithwish Ghosh, Shicheng Jin, Longchuan Bai, Angelo Aguilar, Donna McEachern, Mi Wang, Qiuxia Li, Bo Wen, Duxin Sun, Shaomeng Wang

Published in

Journal of medicinal chemistry. Volume 69. Issue 17. Pages 20520-20539. Sep 10, 2026.

Abstract

KRAS G12D and G12V mutants account for >50% of human cancers carrying a mutated KRAS protein, and targeting KRAS proteins by induced protein degradation represents an attractive cancer therapeutic strategy. Herein, we present the design, synthesis, and evaluation of PROTAC KRAS degraders using a novel cereblon ligand, which led to the discovery of CW-10201 as a promising KRAS degrader. CW-10201 effectively induced degradation of KRASG12D and KRASG12V mutants at low nanomolar concentrations in cells and attained IC50 values of 2-4 nM in inhibition of cell growth in cancer cell lines carrying KRASG12D or KRASG12V mutation. It demonstrated excellent pharmacokinetic and pharmacodynamic properties in mice. CW-10201 was capable of attaining tumor regression in the SW1990 KRASG12D mutated xenograft tumor model and effectively inhibited tumor growth in the SW620 KRASG12V xenograft tumor model in mice at well-tolerated doses. CW-10201 represents a promising KRASG12D and KRASG12V degrader for extensive evaluation and optimization for the treatment of human cancers.

PMID:
42720481
Bibliographic data and abstract were imported from PubMed on 10 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.